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Abstract
Background: Depression in people with diabetes can result in increased risk for diabetes-related complications.
The prevalence of depression has been estimated to be 17.6 % in people with type 2 diabetes mellitus (T2DM),
based on studies published between 1980 and 2005. There is a lack of more recent estimates of depression
prevalence among the US general T2DM population.
Methods: The present study used the US National Health and Nutrition Examination Survey (NHANES) 2005–2012
data to provide an updated, population-based estimate for the prevalence of depression in people with T2DM.
NHANES is a cross-sectional survey of a nationally representative sample of the civilian, non-institutionalized US
population. Starting from 2005, the Patient Health Questionnaire (PHQ-9) was included to measure signs and
symptoms of depression. We defined PHQ-9 total scores ≥ 10 as clinically relevant depression (CRD), and ≥ 15
as clinically significant depression (CSD). Self-reported current antidepressant use was also combined to estimate overall
burden of depression. Predictors of CRD and CSD were investigated using survey logistic regression models.
Results: A total of 2182 participants with T2DM were identified. The overall prevalence of CRD and CSD among
people with T2DM is 10.6 % (95 % confidence interval (CI) 8.9–12.2 %), and 4.2 % (95 % CI 3.4–5.1 %), respectively.
The combined burden of depressive symptoms and antidepressants may be as high as 25.4 % (95 % CI 23.0–27.9 %).
Significant predictors of CRD include age (younger than 65), sex (women), income (lower than 130 % of poverty level),
education (below college), smoking (current or former smoker), body mass index (≥30 kg/m2), sleep problems,
hospitalization in the past year, and total cholesterol (≥200 mg/dl). Significant predictors of CSD also include
physical activity (below guideline) and cardiovascular diseases.
Conclusions: The prevalence of CRD and CSD among people with T2DM in the US may be lower than in earlier
studies, however, the burden of depression remains high. Further research with longitudinal follow-up for depression
in people with T2DM is needed to understand real world effectiveness of depression management.
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Background
Depression can increase the risk of diabetes-related com-
plications in people with diabetes due to poor self-care, re-
duced treatment adherence, and poor glycemic control [1].
The management of comorbid depression and diabetes
through integrated and collaborative care has been shown
to improve medication adherence, glycemic control [2],
and depression outcomes [3]. Routine screening of depres-
sion in adults with diabetes is recommended by the Ameri-
can Association of Clinical Endocrinologists (AACE) [4].
Integrating depression screening with cost-effective treat-
ment strategies has also been recommended for the
general primary care setting [5]. Yet, it has been sug-
gested that few diabetes clinics provide mental health
screening or integrate mental/behavioral health services
in diabetes clinical care, and even the use of brief paper-
and-pencil self-report measures remains rare [6].
There is extensive evidence that depression is a com-
mon comorbidity in people with diabetes [7]. One meta-
analysis reported an overall depression prevalence of 27 %
in people with type 2 diabetes mellitus (T2DM) based on
15 studies published before January 2000 [8]. A later
meta-analysis reported an overall depression prevalence of
17.6 % in people with T2DM compared with 9.8 % in
those without T2DM, based on 10 studies published be-
tween January 1980 and May 2005 with a total of 51,331
people across multiple countries, including the US [9].
There is only a limited number of large, population-based
studies that estimated depression prevalence for people
with T2DM. The Kaiser Permanente Diabetes Registry re-
ported a prevalence of diagnosed depression (based on
diagnosis codes in medical records) to be 17.9 % in
T2DM in 1999 [10]. A study of the 2006 Preventive Be-
havioral Risk Factor Surveillance System (PBRFSS) (a
cross-sectional, random-sample, telephone survey) re-
ported depression prevalence of 24 % in people with
T2DM using insulin, and 17.3 % in people with T2DM
not using insulin (depression was defined as total score
≥10 on the Patient Health Questionnaire, PHQ-8, ad-
ministered in 36 states and territories in 2006) [11].
There is a lack of more recent, US national-level esti-
mates of depression prevalence among a representative
sample of the T2DM population.
The present study used the US National Health and
Nutrition Examination Survey (NHANES) 2005–2012
data to estimate the prevalence of depression, and to
explore potential predictors of clinically relevant and
clinically significant depression (defined below) in a na-
tionally representative sample that includes people with
T2DM.
Methods
The US National Health and Nutrition Examination Sur-
vey (NHANES) is a cross-sectional survey of a nationally
representative sample of the civilian, non-institutionalized
US population, designed to monitor the nation’s health
and nutrition status [12]. NHANES uses a complex, multi-
stage, probability sampling design to select participants,
and continuous data collection has been conducted in
2-year cycles since 1999 [12]. During each 2-year cycle,
about 30 selected counties (i.e., the primary sampling
units) were visited out of approximately 3,000 counties
in the US. Within selected segments of these counties,
letters explaining NHANES were sent to selected
households before trained interviewers visited and ob-
tained informed consent from individuals for participa-
tion. Each 2-year survey cycle has a combined sample of
roughly 10,000 persons and is representative of the civil-
ian, non-institutionalized US population. Overall interview
response rate was roughly 80 % (see Additional file 1).
The survey comprises interviews conducted in partici-
pants’ homes and standardized physical examinations in
mobile examination centers (MECs), including labora-
tory tests. Topics covered by the survey questionnaires
include demographics (e.g., age, sex, race/ethnicity, fam-
ily income-to-poverty ratio [13], education, and marital
status), general health (e.g., hospitalization in the past
year, weight change history, hours of sleep, sleep prob-
lems), behavior and lifestyle variables (e.g., smoking, alco-
hol, physical activities, substance use), disease history (e.g.,
whether they have been diagnosed by health professionals
to have diabetes, hypertension, cancer, cardiovascular dis-
eases, liver disease). NHANES participants reported pre-
scription medication use during a one-month period prior
to the survey date, and were asked to show the interviewer
their medication containers during the household inter-
view. Lexicon Plus®, a proprietary database of Cerner
Multum, Inc. [14] was used in NHANES to assist with
medication data collection, data editing and release. The
Lexicon Plus® is a comprehensive database of all prescrip-
tion and some nonprescription drug products available in
the US drug market. We identified antidepressants using
the Lexicon Plus® therapeutic classification (first-level
category “PSYCHOTHERAPEUTIC AGENTS”, second-
level category “ANTIDEPRESSANTS”), which included
selective serotonin reuptake inhibitors [SSRI], monoamine
oxidase inhibitors [MAOI], tricyclic antidepressants [TCA],
serotonin-norepinephrine reuptake inhibitors [SNRI],
phenylpiperazine and miscellaneous antidepressants [15].
About 85 % of the self-reported use of antidepressants had
a record of “prescription container seen by the interviewer”.
Starting from 2005, NHANES has included the Patient
Health Questionnaire (PHQ-9) [16, 17] to measure signs
and symptoms of depression. The PHQ-9 and some
other computer-assisted personal interviews, and an-
thropometrics (e.g., body weight, height, waist-to-height
ratio) as well as bio-specimens are taken in the MEC ac-
cording to standardized protocols. The PHQ-9 is a 9-
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item depression screening instrument that asks about
the frequency of symptoms of depression over the past
2 weeks [16, 17]. Total PHQ-9 score ranges from 0 to 27
and are categorized as “none or minimum” (0–4), “mild”
(5–9), “moderate” (10–14), “moderately severe” (15–19),
and “severe” (20–27) for depression severity. In this
study, we combined scores 10–27 (“moderately severe or
severe”) to improve precision of estimates. We defined
PHQ-9 total scores ≥ 10 as clinically relevant depression
(CRD) [18], which is consistent with depression process/
outcome performance measures recommended by the
National Quality Forum [19]. PHQ-9 score ≥10 has shown
a sensitivity of 88 % and a specificity of 88 % for major de-
pression [17]. In addition, those with PHQ-9 scores ≥ 15
(a subset of those with PHQ-9 scores ≥10) were catego-
rized as clinically significant depression (CSD), which sug-
gests the presence of major depression for which active
treatment with pharmacotherapy and/or psychotherapy is
recommended [17]. Participants reporting current anti-
depressant use were also included as prevalent cases in
the estimation of overall burden of depressive symptoms
because this may imply CRD and/or CSD. Because some
antidepressants are also indicated for other psychiatric
symptoms (e.g., anxiety), and because the reasons for tak-
ing antidepressants were not available from NHANES, we
conducted sensitivity analyses of various combinations of
PHQ-9 score, antidepressant use and consultation with
mental health professionals. We also analyzed question 9
of the PHQ-9 questionnaire which asks about suicidal
ideation. The specificity of the PHQ-9 suicide screening
item was 0.84 and sensitivity was 0.69 in a study of 166
people from 2 primary care clinics in the US, which sug-
gested it may be useful in primary care practice to identify
individuals at risk for suicide [20]. In addition to the
PHQ-9 questions, NHANES also assesses the difficulty
caused by the depressive symptoms with work, taking care
of things at home, or getting along with people, using a
scale of ‘not at all’ to extremely difficult.
We identified people with T2DM using the following cri-
teria [21, 22]: self-reported diagnosis of diabetes or “sugar
diabetes” at age ≥ 30 years, not initiating insulin therapy
within 1 year of diabetes diagnosis, and not pregnant at the
time of interview/examination. Diabetes-related variables
such as age at diagnosis, self-monitoring of blood glucose,
diabetes complications and antihyperglycemic medications
were based on NHANES diabetes questionnaire data, lab/
exam variables such as glycohemoglobin (HbA1c), choles-
terol, and blood pressure were based on NHANES
MEC data.
Analyses were weighted, and accounted for the stratified,
multistage probability sampling design of NHANES and
survey nonresponse. Logistic regression models were used
to select predictors of CRD and CSD in T2DM from po-
tential candidate variables [9, 23], including demographics,
general health, behavior and lifestyle, disease history, lab
and prescription medications. First, univariable association
of all the potential predictors were evaluated (i.e., entered
into the survey logistic regression models one at a time),
and those with statistically significant association with
CRD and/or CSD were then entered together into a multi-
variable regression model. The final multivariable model
retained all variables that remained statistically significant.
Statistical significance was assessed by two-sided P values
of < 0.05, with no adjustments for multiple testing. Odds
ratio (OR) and 95 % confidence intervals (CI) were esti-
mated and presented for predictors selected in the final
models. We did not use stepwise automated model se-
lection because the effective degrees of freedom are
bounded by the number of clusters (i.e., primary sam-
pling units in NHANES), which makes such methods
problematic [24–26]. We also compared analyses that
excluded missing PHQ-9 data with analyses that com-
bined missing PHQ-9 data with the non-CRD and non-
CSD categories.
We also evaluated whether there was a temporal trend
in the prevalence of depressive symptoms or antidepres-
sant use over the 8 years (i.e., 4 NHANES survey cycles).
This was done by fitting NHANES survey cycle as a con-
tinuous variable in the survey regression models. All
analyses were performed using SAS (SAS Institute Inc.,
Cary, NC, USA), version 9.2.
Results
There were a total of 40,790 participants in the NHANES
2005–2012 (which represents the total US civilian, non-
institutionalized population of 299.3 million people).
Among these, a total of 2,648 respondents reported that
they had been “told by a doctor or health professional”
that they had “diabetes or sugar diabetes” (this sample
represents 18.8 million people with diagnosed diabetes).
From the 2,648 respondents, we identified 2,182 partici-
pants with T2DM by our definition and who had data for
both the interview and physical examination. Among the
2,182 respondents with T2DM, 235 (10.8 %) had missing
data on one or more items of the PHQ-9 questionnaire,
including 37 (1.7 %) taking antidepressants. We compared
analyses that excluded missing PHQ-9 data with analyses
that combined the missing data with the non-CRD and
non-CSD categories. Results were similar and the latter
are presented.
Tables 1 and 2 describe the general characteristics of
people with T2DM according to clinically relevant depres-
sion (CRD, defined by PHQ-9 total score > =10) and clinic-
ally significant depression (CSD, defined by PHQ-9 total
score > =15). (See Additional file 2 for the descriptions ac-
cording to the four PHQ-9 categories). Overall, the categor-
ies for more severe depression have a higher proportion of
T2DM subjects who were younger, women, minority
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Table 1 Characteristics of people with T2DM by clinically relevant depression, NHANES 2005–2012
Non-CRD CRD Overall
N, participants (%) 1926 (88.3) 256 (11.7) 2182 (100.0)
Frequency, weighteda (%) 13,520,141(89.4) 1,597,475(10.6) 15,117,616 (100.0)
Age group, %
30–49 years 15.4 27.5 16.6
50–64 years 38.1 43.7 38.7
65–74 years 26.7 18.8 25.8
≥ 75 years 19.9 10.0 18.8
Sex, %
Male 50.8 30.7 48.7
Female 49.2 69.3 51.3
Race, %
Non-Hispanic white 61.1 54.6 60.4
Non-Hispanic black 17.3 21.6 17.8
Mexican and other Hispanic 12.9 19.9 13.6
Other 8.7 3.9 8.2
Ratio of family income to poverty level≤ 1.3, % 20.8 52.1 24.1
Marital status, single or living alone, % 36.3 54.5 38.3
Education, %
College or above 47.2 31.6 45.5
High school graduate 25.3 22.6 25.0
Below high school 27.5 45.8 29.4
Smoking
Non-smoker 51.0 39.3 49.8
Past 36.0 28.5 35.2
Current 13.0 32.2 15.0
Alcohol
Non-drinker 42.4 49.4 43.2
Above moderate level 16.0 21.2 16.6
Moderate drinking 41.5 29.4 40.2
Marijuana, ever use, % 16.5 28.9 17.8
Physical activity level met guidelines,b % 43.1 26.7 41.4
Cardiovascular diseases 28.0 36.4 28.8
Diabetic retinopathy 18.0 25.4 18.8
Hypertension 81.7 81.5 81.7
Liver diseases 4.1 7.7 4.5
Cancer 17.4 18.5 17.5
Weak/failing kidneysc 7.3 12.2 7.8
Overnight hospitalization in the past year, % 20.5 44.0 23.0
My health in general is, %
Excellent, very good 16.3 2.5 14.8
Good/Fair 69.6 65.2 69.1
Poor 6.5 32.4 9.2
Missing 7.7 0.0 6.9
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Table 1 Characteristics of people with T2DM by clinically relevant depression, NHANES 2005–2012 (Continued)
Hours of sleep per day, %
< =5 h 16.2 38.5 18.6
6-8 h 74.1 50.7 71.6
> =9 h 9.1 9.9 9.2
Missing 0.5 1.0 0.6
Self-reported having trouble sleep, % 33.8 65.2 37.1
Told by doctor having sleep disorders, % 15.7 29.9 17.2
Age at diabetes diagnosis, years
Mean (s.e.) 52.6 (0.4) 48.9 (0.9) 52.2 (0.4)
Categories, %
< 50 41.6 55.6 43.0
50–69 47.9 38.3 46.8
> =70 9.8 4.8 9.3
Missing 0.8 1.3 0.8
Duration of diabetes
Mean (s.e.) 10.0 (0.2) 8.9 (0.7) 9.9 (0.2)
Categories, %
< 5 years 30.8 28.3 30.5
5–9 years 23.9 29.9 24.5
> =10 years 44.5 40.6 44.1
Missing 0.8 1.3 0.8
HbA1c, %
Mean (s.e.) 7.3 (0.1) 7.4 (0.2) 7.3 (0.1)
Categories, %
< 6.5 % 34.8 34.0 34.7
6.5- < 7.5 % 29.1 25.3 28.7
7.5–8.9 % 18.9 17.9 18.8
> =9 % 13.0 13.4 13.0
Missing 4.2 9.5 4.7
Total cholesterol (mg/dl)
Mean (s.e.) 182.0 (1.6) 193.1 (3.7) 183.1 (1.5)
Categories
> 0 and <200 65.8 49.8 64.1
> =200 27.9 39.9 29.2
Missing 6.3 10.3 6.7
LDL cholesterol(mg/dl)
Mean (s.e.) 98.1 (1.4) 108.4 (4.1) 99.0 (1.4)
Categories
> 0 and <100 52.7 44.9 52.0
> =100 39.4 48.5 40.2
Missing 7.9 6.6 7.8
HDL cholesterol (mg/dl)
Male and female, mean (s.e.) 47.8 (0.4) 45.8 (1.1) 47.6 (0.4)
Male, mean (s.e.) 44.2 (0.5) 41.2 (2.0) 44.0 (0.5)
Female, mean (s.e.) 51.7 (0.7) 48.0 (1.2) 51.2 (0.7)
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Table 1 Characteristics of people with T2DM by clinically relevant depression, NHANES 2005–2012 (Continued)
Categories, %
Male > 40 and female > 50 49.7 36.9 48.4
Male < =40 and female < =50 43.9 52.8 44.9
Missing 6.3 10.3 6.7
Triglycerides (mg/dl)
Mean (s.e.) 176.3 (9.8) 180.1 (14.0) 176.6 (9.4)
Categories
> 0 and <150 55.6 46.3 54.8
> =150 41.8 50.4 42.6
Missing 2.5 3.3 2.6
Blood pressure (BP), mmHg
SBP, mean (s.e.) 130.6 (0.6) 128.6 (1.4) 130.4 (0.5)
DBP, mean (s.e) 68.4 (0.5) 70.7 (1.0) 68.6 (0.4)
SBP < 140, DBP < 90 67.1 72.3 67.5
Missing 4.9 2.3 4.6
Medications
Insulin, % 27.0 24.7 26.8
Sulfonylureas, % 35.8 27.0 34.8
THIAZOLIDINEDIONES, % 17.5 14.3 17.1
Meglitinides, % 2.0 0.2 1.8
DPP-4 INHIBITORS, % 7.6 1.4 6.9
GLP-1 AGONISTS, % 1.5 1.8 1.5
Metformin, % 52.2 59.7 53.0
Any antihyperglycemic agents 88.1 87.3 88.0
Antihypertensives, % 76.7 76.0 76.6
Statins, % 54.3 52.0 54.1
Body mass index, kg/m2
Mean (s.e.) 32.5 (0.3) 35.5 (0.6) 32.8 (0.2)
Categories, %
< 25 13.9 8.2 13.3
25- < 30 26.7 11.0 25.0
30- < 35 27.4 37.1 28.5
35+ 31.9 43.7 33.2
Missing 0.1 0.0 0.1
Waist-to-height ratio, mean (s.e.) 0.659 (0.004) 0.699 (0.007) 0.663 (0.003)
Categories, %
0.3- < 0.5 2.4 1.4 2.3
0.5- < 0.7 62.6 48.4 61.1
≥ 0.7 26.8 40.2 28.2
Missing 8.3 10.0 8.5
Values are % unless stated otherwise, percentages may not add up exactly to 100 due to rounding
CRD clinically relevant depression, defined by PHQ-9 score ≥ 10; S.e. = standard error
aThere were 466 participants (=2,648-2,182) who reported having diagnosed diabetes but were not included in this analysis (due to presumed type 1 diabetes or
non-participation in the MEC exams), representing 3,653,851 (=18,771,467-15,117,616) people with diabetes in the US civilian, non-institutionalized population
bPhysical activity level evaluated according to the 2008 Physical Activity Guidelines for Americans [36]
cA “yes” answer to “Have you ever been told by a doctor or other health professional that you have weak or failing kidneys (excluding kidney stones, bladder
infections, or incontinence)?”
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Table 2 Characteristics of people with T2DM by clinically significant depression, NHANES 2005–2012
Non-CSD CSD Overall
N, participants 1926 (88.3) 256 (11.7) 2182
Frequency, weighteda (%) 13,520,141(89.4) 1,597,475(10.6) 15,117,616 (100.0)
Age group, %
30–49 years 16.3 25.4 16.6
50–64 years 38.2 50.3 38.7
65–74 years 26.3 15.4 25.8
≥ 75 years 19.3 8.9 18.8
Sex, %
Male 49.5 29.4 48.7
Female 50.5 70.6 51.3
Race, %
Non-Hispanic white 60.8 50.6 60.4
Non-Hispanic black 17.6 23.4 17.8
Mexican and other Hispanic 13.3 21.8 13.6
Other 8.3 4.2 8.2
Ratio of family income to poverty level≤ 1.3, % 22.4 62.9 24.1
Marital status, single or living alone, % 37.6 53.3 38.3
Education, %
College or above 46.5 23.7 45.5
High school graduate 25.3 19.5 25.0
Below high school 28.2 56.8 29.4
Smoking
Non-smoker 50.2 39.1 49.8
Past 35.7 24.7 35.2
Current 14.1 36.1 15.0
Alcohol
Non-drinker 42.5 58.9 43.2
Above moderate level 16.4 20.3 16.6
Moderate drinking 41.1 20.8 40.2
Marijuana, ever use, % 17.3 29.3 17.8
Physical activity level met guidelines,b % 42.5 16.9 41.4
Cardiovascular diseases 28.3 41.9 28.8
Diabetic retinopathy 18.8 18.6 18.8
Hypertension 81.8 79.1 81.7
Liver diseases 4.2 11.9 4.5
Cancer 17.3 23.8 17.5
Weak/failing kidneysc 7.6 13.1 7.8
Overnight hospitalization in the past year, % 22.1 42.5 23.0
My health in general is, %
Excellent, very good 15.4 1.2 14.8
Good/Fair 69.4 61.7 69.1
Poor 8.0 37.1 9.2
Missing 7.2 0.0 6.9
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Table 2 Characteristics of people with T2DM by clinically significant depression, NHANES 2005–2012 (Continued)
Hours of sleep per day, %
< =5 h 17.5 43.5 18.6
6–8 h 73.0 40.2 71.6
> =9 h 8.9 15.6 9.2
Missing 0.6 0.7 0.6
Self-reported having trouble sleep, % 35.7 69.2 37.1
Told by doctor having sleep disorders, % 16.3 38.2 17.2
Age at diabetes diagnosis, years
Mean (s.e.) 52.4 (0.4) 48.4 (1.3) 52.2 (0.4)
Categories, %
< 50 42.5 56.1 43.0
50–69 47.3 37.2 46.8
> =70 9.5 4.8 9.3
Missing 0.8 1.9 0.8
Duration of diabetes
Mean (s.e.) 9.9 (0.2) 9.6 (1.0) 9.9 (0.2)
Categories, %
< 5 years 30.9 21.1 30.5
5–9 years 24.3 29.3 24.5
> =10 years 43.9 47.6 44.1
Missing 0.8 1.9 0.8
HbA1c, %
Mean (s.e.) 7.3 (0.1) 7.4 (0.2) 7.3 (0.1)
Categories, %
< 6.5 % 34.9 31.7 34.7
6.5- < 7.5 % 28.7 28.7 28.7
7.5–8.9 % 19.1 11.9 18.8
> =9 % 12.9 15.0 13.0
Missing 4.4 12.8 4.7
Total cholesterol (mg/dl)
Mean (s.e.) 182.6 (1.6) 195.3 (5.3) 183.1 (1.5)
Categories
> 0 and <200 65.1 42.4 64.1
> =200 28.5 43.4 29.2
Missing 6.4 14.2 6.7
LDL cholesterol(mg/dl)
Mean (s.e.) 98.5 (1.4) 112.9 (6.0) 99.0 (1.4)
Categories
> 0 and <100 52.5 38.9 52.0
> =100 39.7 54.3 40.2
Missing 7.8 6.8 7.8
HDL cholesterol (mg/dl)
Male and female, mean (s.e.) 47.7 (0.4) 45.1 (1.7) 47.6 (0.4)
Male, mean (s.e.) 44.1 (0.5) 38.7 (2.7) 44.0 (0.5)
Female, mean (s.e.) 51.3 (0.7) 48.0 (1.6) 51.2 (0.7)
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Table 2 Characteristics of people with T2DM by clinically significant depression, NHANES 2005–2012 (Continued)
Categories, %
Male > 40 and female > 50 49.1 31.7 48.4
Male < =40 and female < =50 44.5 54.0 44.9
Missing 6.4 14.2 6.7
Triglycerides (mg/dl)
Mean (s.e.) 177.1 (9.7) 162.4 (14.7) 176.6 (9.4)
Categories
> 0 and <150 55.1 47.6 54.8
> =150 42.5 45.5 42.6
Missing 2.4 6.8 2.6
Blood pressure (BP), mmHg
SBP, mean (s.e.) 130.5 (0.6) 126.6 (2.1) 130.4 (0.5)
DBP, mean (s.e) 68.6 (0.4) 68.8 (1.9) 68.6 (0.4)
SBP < 140, DBP < 90 67.7 64.3 67.5
Missing 4.6 4.5 4.6
Medications
Insulin, % 26.6 30.3 26.8
Sulfonylureas, % 35.4 22.1 34.8
THIAZOLIDINEDIONES, % 17.5 9.9 17.1
Meglitinides, % 1.8 0.4 1.8
DPP-4 INHIBITORS, % 7.3 0.0 6.9
GLP-1 AGONISTS, % 1.5 2.9 1.5
Metformin, % 53.0 53.7 53.0
Any antihyperglycemic agents 88.3 81.6 88.0
Antihypertensives, % 76.8 73.2 76.6
Statins, % 54.5 45.2 54.1
Body mass index, kg/m2
Mean (s.e.) 32.7 (0.2) 34.4 (0.7) 32.8 (0.2)
Categories, %
< 25 13.5 9.6 13.3
25- < 30 25.5 13.5 25.0
30- < 35 28.1 35.9 28.5
35+ 32.8 41.0 33.2
Missing 0.1 0.0 0.1
Waist-to-height ratio, mean (s.e.) 0.662 (0.003) 0.691 (0.010) 0.663 (0.003)
Categories, %
0.3- < 0.5 2.3 1.8 2.3
0.5- < 0.7 61.7 46.5 61.1
≥ 0.7 27.8 37.4 28.2
Missing 8.2 14.3 8.5
Values are % unless stated otherwise, percentages may not add up exactly to 100 due to rounding. CSD Clinically significant depression, defined by PHQ-9
score ≥ 15; S.e. = standard error
aThere were 466 participants (=2,648-2,182) who reported having diagnosed diabetes but were not included in this analysis (due to presumed type 1 diabetes or
non-participation in the MEC exams), representing 3,653,851 (=18,771,467-15,117,616) people with diabetes in the US civilian, non-institutionalized population
bPhysical activity level evaluated according to the 2008 Physical Activity Guidelines for Americans [42]
cA “yes” answer to “Have you ever been told by a doctor or other health professional that you have weak or failing kidneys (excluding kidney stones, bladder
infections, or incontinence)?”
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ethnicities (i.e., not non-Hispanic White), single or liv-
ing alone, less physically active, having lower income,
lower education level, sleep problems, cardiovascular
diseases, cancer, liver and kidney diseases.
Figure 1 plots prevalence estimates of CRD and CSD.
Between 2005 and 2012, the prevalence of CRD among
people with T2DM is 10.6 % overall (95 % CI 8.9–12.2 %),
and the prevalence is higher in women than in men. Simi-
larly, the overall T2DM population prevalence of CSD is
4.2 % (95 % CI 3.4–5.1 %). However, when antidepressant
medication is taken into consideration, the combined
burden of depression may be as high as 25.4 % overall
(95 % CI 23.0–27.9 %). In a sensitivity analysis that re-
moved some common antidepressants (see Table 3, last
row) approved for other psychiatric indications (mainly
anxiety and related disorders) in the US, the overall bur-
den of CRD and/or antidepressants was 16.7 % (95 % CI
14.6–18.9 %), and the overall burden of CSD and/or anti-
depressants was 10.8 % (95 % CI 8.9–12.7 % in people
with T2DM. In women, the corresponding prevalence
were 20.5 % (95 % CI 16.7–24.3 %), and 12.3 % (95 % CI
9.2–15.4 %); in men, the corresponding prevalence were
12.7 % (95 % CI 10.5–15.0 %) and 9.2 % (95 % CI 7.3–
11.1 %), respectively. There was a statistically significant
trend in the prevalence of CRD and CSD, which increased
early on and then stabilized from the 2009–2010 to the
2011–2012 period (Additional file 3). The increasing trend
was noted at higher PHQ-9 scores (i.e., PHQ-9 score ≥ 15
and PHQ-9 score ≥ 20). No significant trend was detected
in the prevalence of antidepressant use, although there
appeared to be a drop in antidepressant use from the
2005–2006 to the 2007–2008 period. We did not find any
notable differences in missing data pattern for PHQ-9 data
across these years.
Table 3 characterized the general impact on health and
life according to the severity of depressive symptoms based
on PHQ-9 scores. Among people with T2DM who had
moderately severe or severe depressive symptoms (PHQ-9
score ≥ 15), 23.2 % reported that these problems made it
extremely difficult for them to do their work, take care of
things at home, or get along with people. In contrast, less
than 1 % of those with none or minimal depressive symp-
toms (PHQ-9 score 0–4) reported such negative impact.
Further, about 1 in 5 of the subjects with moderately severe
or severe depressive symptoms reported having suicidal
thoughts nearly every day. Well over half of the people
with moderately severe or severe depressive symptoms re-
ported poor mental health and poor physical health over
half of the past 30 days. With respect to combined impact
of poor mental and poor physical health, 55.3 % of people
with moderately severe or severe depressive symptoms
reported that poor physical or poor mental health kept
them from usual activities such as self-care, work, school
or recreation in more than half of the past 30 days. About
half of the people with moderate or severe depressive
symptoms reported taking antidepressants, but only 1 in 7
reported having seen or talked to a mental health profes-
sional such as a psychologist, psychiatrist, psychiatric
nurse, or clinical social worker about their health during
the past 12 months.
Figure 2 plots the mean PHQ-9 scores for statistically
significant variables in the univariate analysis that were as-
sociated with CRD (i.e., PHQ-9 score ≥ 10), and corre-
sponding crude odds ratio (OR) estimates from the survey
logistic regression models. Overall, the mean PHQ-9 total
score in people with T2DM was 3.9 (95 % CI 3.6–4.1).
The OR estimates are consistent with descriptions in
Table 1, for example, people with T2DM in the age cat-
egory of 30–49 were almost 3-fold as likely to have CRD
as those aged 65 years or older, with OR = 2.9 (95 % CI
1.9–4.5). Female sex is associated with an OR of 2.3 (95 %
CI 1.7–3.3) for CRD. Lower income (family income less
than 130 % of poverty level) is associated with an OR of
4.1 (95 % CI 2.8–6.0) for CRD. Body mass index greater
than 30 (i.e., obesity) or 35 (i.e., severe obesity) is associ-
ated with CRD with ORs about 2.
Fig. 1 Prevalence of CRD, CSD and antidepressant treatment in T2DM, NHANES 2005–2012. Legends: prevalence in men and women with T2DM
overall shown by “-”, in men with T2DM by “x”, and in women with T2DM by “o”, respectively. Vertical lines extend from lower to upper 95 %
confidence limits of the corresponding prevalence estimates. CRD, clinically relevant depression, defined by PHQ score ≥10; CSD, clinically significant
depression, defined by PHQ score ≥15; AD, currently taking antidepressants
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Table 3 Mental health status by severity of depressive symptoms
Characteristic PHQ-9 depression score Overall





Difficulty with work, life, people due to depressive symptoms, %
Not at all 48.0 56.5 37.6 22.3 2.8 43.4
Somewhat 9.5 39.6 42.1 22.2 1.4 16.5
Very 0.8 2.8 17.0 31.6 0.4 3.4
Extreme 0.2 1.1 3.3 23.2 0.5 1.5
Missing 41.6 0.0 0.0 0.7 94.9 35.2
Suicidal ideation, %
Not at all 99.5 90.4 83.9 55.6 6.2 86.3
Several days 0.5 8.9 14.4 13.9 0.7 3.4
More than half the days 0 0.3 0.8 11.1 0.2 0.6
Nearly every day 0 0.4 0.9 19.4 0 0.9
Missing 0 0 0 0 92.9 8.8
# of days mental health not good during the past 30 days
Mean (s.e.) 2.0 (0.2) 6.9 (0.6) 13.4 (1.3) 19.5 (1.3) 5.4 (1.4) 4.6 (0.3)
Categories, %
< 15 days 94.4 80.5 53.6 30.5 21.4 79.9
> =15 and < =30 5.5 19.4 46.4 68.2 4.0 13.0
Missing 0.1 0.1 0.0 1.3 74.6 7.2
# of days physical health not good during the past 30 days
Mean (s.e.) 3.9 (0.3) 8.7 (0.8) 16.1 (1.3) 18.9 (1.3) 6.3 (1.4) 6.4 (0.3)
Categories, %
< 15 days 89.0 73.9 46.8 36.6 20.8 75.1
> =15 and < =30 10.8 26.1 53.2 62.9 5.4 17.8
Missing 0.2 0.1 0.0 0.5 73.8 7.1
# of days during the past 30 days, poor physical/mental health
kept from doing usual activities, such as self-care, work, school
or recreation
Mean (set 77, 99 = .) 1.8 (0.2) 5.2 (0.7) 11.8 (1.4) 15.4 (1.7) 6.7 (1.8) 3.9 (0.3)
Categories, %
< 15 days 94.9 84.0 63.2 43.0 19.8 81.7
> =15 and < =30 4.9 15.9 36.8 55.3 6.4 11.1
Missing 0.2 0.1 0.0 1.7 73.8 7.2
Seen mental health professional past 12 months, % 9.1 7.4 12.6 14.0 8.4 9.2
Antidepressants, % 14.1 24.9 42.2 49.4 18.1 19.6
SSRI, % 8.9 15.6 24.2 31.5 11.2 12.2
SSNRI, % 2.1 2.8 10.7 9.0 4.7 3.3
Duloxetine, % 1.0 0.3 1.1 0.0 0.9 0.8
TCA, % 2.3 5.5 8.1 10.1 1.2 3.4
Miscellaneous, % 3.5 3.3 8.1 11.7 4.1 4.1
-OPD, % 7.6 5.8 7.0 6.8 4.2 6.9
SSRI selective serotonin reuptake inhibitors, SSNRI serotonin-norepinephrine reuptake inhibitors, TCA tricyclic antidepressants, Miscellaneous antidepressants
include bupropion, vilazodone, maprotiline, mirtazapine, nefazodone and trazodone. -OPD: excluding antidepressants that are also approved for other psychiatric
disorders: SSRIs escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and SSNRI venlafaxine
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We also evaluated uni-variable associations with CSD
(i.e., PHQ-9 score ≥ 15); variables that achieved statis-
tical significance were a subset of those identified for
CRD above. The mean PHQ-9 scores and the OR esti-
mates for these variables were also plotted (Additional
file 4) and overall, the OR estimates for the variables in
association with CSD appeared larger than the corre-
sponding estimates for CRD.
Table 4 presents results of multi-variable regression
models that only retained statistically significant predic-
tors for CRD and CSD. Significant predictors of CRD
include age, gender, income, education, smoking, body
mass index, sleep problems, hospitalization in the past
12 months, and total cholesterol not at goal (≥200 mg/
dl). Significant predictors of CSD include age, gender,
income, education, physical activity, sleep problems,
cardiovascular diseases, and total cholesterol not at goal
(≥200 mg/dl).
Discussion
To the best of our knowledge, this study is the first to
provide a US national level estimates of depression
prevalence for people with T2DM [8, 9].
We estimated an overall point prevalence of 10.6 %
(95 % CI 8.9–12.2) for clinically relevant depression
(CRD, PHQ-9 score ≥ 10) in people with T2DM, which
is about 1.56 times that of the general US adult population
(6.8 % using NHANES data 2005–2008) [27]. Similarly,
our overall prevalence estimate of 4.2 % for clinically sig-
nificant depression (CSD, PHQ-9 score ≥ 15) in people
with T2DM is about 1.75 times that of the general US
adult population (2.4 %) [27]. Interestingly, our study
found that 49.4 % of the T2DM people with CSD reported
taking antidepressants, which is about 1.55 times of the
31.8 % reported for the general US adult population with
CSD [27]. This suggests that people with T2DM who had
CSD are more likely to receive antidepressant medications
Fig. 2 Mean (95 % CI) of PHQ-9 score (panel a) and crude ORs for CRD (panel b). Legends: squares mark out mean estimates while horizontal
lines spread 95 % confidence interval, the green vertical dotted-line indicates overall grand mean of PHQ-9 score (as a continuous variable) for all
T2DM, not stratified by any specific characteristics. Panel a shows the mean (95 % CI) of continuous PHQ-9 score according to various characteristics
in T2DM, Panel b shows corresponding crude odds ratio (OR) for clinically relevant depression (CRD), defined by PHQ-9 ≥ 10. CVD, cardiovascular
diseases; HDLc, high-density lipoprotein cholesterol; TC, total cholesterol. BMI, body mass index; PA, physical activity. While PHQ-9 score ranges
from 0 to 27, x-axis is not drawn to full 27 points to save space
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than in the general population of the US with CSD. This
could be due to the higher rate of interaction of subjects
with T2DM with health care providers. Likewise, when we
consider antidepressant medication in combination with
CRD, the burden of depressive symptoms on people with
T2DM overall may be about 25.4 %, and in women it may
be as high as about 32 % (Fig. 1).
A previous meta-analysis based on studies before 2005
has reported depression prevalence of 17.6 % among
people with T2DM, which appeared higher than our esti-
mated prevalence for CRD and CSD, but lower than our
estimate of the burden of depression combined with anti-
depressant treatment. This may suggest that recognition
and treatment of depression has improved for people with
T2DM, even though some people may be taking the anti-
depressant medications for symptoms or diseases other
than depression, or perhaps physicians may prescribe
more antidepressants to people with chronic diseases. For
example, duloxetine is a selective serotonin and norepin-
ephrine reuptake inhibitor (SNRI) antidepressant that is
also indicated for neuropathic pain for people with T2DM.
However, only 0.8 % of people with T2DM reported taking
duloxetine (Table 3). In a sensitivity analysis that excluded
antidepressants approved for other psychiatric disorders
(mainly anxiety and related disorders, see Table 3, last
row), our estimated overall prevalence of CRD and/or anti-
depressants was 16.7 % (95 % CI 14.6–18.9 %) in people
with T2DM. These estimates are likely too conservative
(i.e., underestimation of the prevalent burden of depression
among people with T2DM) because of (1) the assumption
that none of the excluded common antidepressants were
taken for depressive symptoms, or none affected PHQ-9
scores at all, and (2) the common comorbidity of depres-
sion and other psychiatric conditions, particularly anxiety
disorders. For example, one Canadian community-based
study of about 2,000 people with T2DM [28] found 74 %
Table 4 ORs (95 % CIs) of statistically significant predictors for CRD and CSD in the multivariable model




Age, years 30–49 2.0 (1.3–3.3) 3.3 (1.5–7.0)
50–64 1.5 (1.0–2.2) 3.3 (2.0–5.5)
≥65 1.0 (ref.) 1.0 (ref.)
Sex Male 1.0 (ref.) 1.0 (ref.)
Female 2.1 (1.4–3.1) 1.8 (1.0–2.9)
Family income/poverty ratio > 1.3 1.0 (ref.) 1.0 (ref.)
≤ 1.3 2.8 (1.8–4.4) 3.1 (1.6–5.8)
Education level Below high school 2.0 (1.3–3.1) 3.1 (1.7–5.6)
High school graduate 1.3 (0.7–2.4) 1.5 (0.7–3.0)
College or above 1.0 (ref.) 1.0 (ref.)
Physical Activity levela Below guideline – 1.0 (ref.)
Met guideline – 0.4 (0.2–0.7)
Smoking status Non-smoker 1.0 (ref.) 1.0 (ref.)
Former smoker 1.3 (0.9–2.0) –
Current smoker 2.4 (1.7–3.6) –
Body Mass Index, kg/m2 < 25 1.0 (ref.) –
25–29 0.9 (0.4–1.8) –
30–34 3.0 (1.6–5.5) –
≥ 35 2.4 (1.3–4.6) –
Sleeping status No trouble 1.0 (ref.) 1.0 (ref.)
Have trouble 3.0 (2.1–4.2) 3.7 (2.4–5.7)
Hospitalized in the past 12 months No 1.0 (ref.) –
Yes 2.6 (1.8–3.7) –
Cardiovascular diseases No – 1.0 (ref.)
Yes – 2.2 (1.3–3.8)
Total cholesterol, mg/dL < 200 1.0 (ref.) 1.0 (ref.)
≥ 200 1.7 (1.2–2.4) 2.0 (1.2–3.6)
CI confidence interval, OR odds ratio, ref. reference; aPhysical activity level evaluated according to the 2008 Physical Activity Guidelines for Americans [42]
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(135 of 183) of people with above-threshold anxiety symp-
toms (defined as score ≥ 10 on the 7-item Generalized
Anxiety Disorder Questionnaire (GAD-7)) also had comor-
bid depression symptoms (defined as PHQ-9 score ≥ 10).
We conducted extensive literature search but couldn’t find
data on the prevalence of comorbid depression and anxiety
among people with diabetes in the US, consistent with the
observation made by the Canadian study that “despite this
frequently observed co-morbidity, there is little research
that explicitly looks at both anxiety and depression in
people with diabetes.” Even in the general US population,
we only found one publication that provided data (in their
Supplemental Table S3) for estimating the prevalence of
co-morbid depression among people with anxiety [29]:
among participants in the Detroit Neighborhood Health
Study, 2008–2010, 78.9 % of those with anxiety (defined as
GAD-7 score 15–21) also had depression (defined as modi-
fied PHQ-9 with cutoff 3+). The prevalence of (self-re-
ported physician diagnosed) diabetes was 18.3 % among a
total of 1,050 participants in that study. Furthermore, the
prevalence of PHQ-9 score ≥10, and/or having seen a men-
tal health professional in the past 12 months, and/or taking
antidepressants (excluding the 6 antidepressants with
multiple indications) was 22.7 % (95 % CI 20.0–25.4 %)
(Additional file 3). Additional analyses showed consist-
ent positive correlation between taking antidepressants
and higher PHQ-9 scores (Additional file 5).
Depression by itself has been associated with reduced
quality of life, loss of work days, damage to relationships,
and even suicide [30, 31]. Our study has found such nega-
tive impact to be particularly concentrated among people
with moderately severe or severe depressive symptoms
(PHQ-9 score ≥ 15), and antidepressant treatment alone
may not have achieved remission of depressive symptoms
for them [32]. Although NHANES is a large, nationally
representative survey that provides comprehensive data,
the cross-sectional data does not provide longitudinal
follow-up, and effectiveness of depression medications
cannot be evaluated.
Cross-sectional studies cannot clarify whether patients
are depressed because they have disabling and worrisome
diabetes complications, or whether having depression could
actually precede occurrence of diabetes complications [33].
The biological mechanisms by which depression and type 2
diabetes are associated remain unclear [34]. In addition
to a growing body of literature indicating a bidirec-
tional association between these two serious long-term
diseases [35], shared biological and behavioral pathways
that may simultaneously predispose to both disorders
have been proposed [36].
Depression prevalence estimates may also depend on the
clinical and methodological settings, such as clinical versus
community, self-reported questionnaires versus standard-
ized diagnostic interviews, etc. [8]. Used most often in
primary care settings, the PHQ-9 has been shown to be a
reliable and valid tool for screening depression [37], includ-
ing in the elderly [38], and has been applied in studies of
diabetes [39]. In fact, some primary care practices were
able to integrate PHQ-9 questionnaire with electronic
health records (EHR), and such enriched medical re-
cords have helped provide higher quality care for de-
pression [40]. Even sub-clinical depression is associated
with worse self-care behavior, and may affect all aspects
of diabetes treatment [5]. We have identified some eas-
ily measured significant predictors for CRD and CSD,
which may help with targeted depression screening. Re-
sults of stratified analysis by common comorbidities in
T2DM (regardless of statistical significance) are given
in additional file 6. The management of recognized de-
pression in people with T2DM mainly involves psycho-
therapy, antidepressant medications, and collaborative
care that commonly employs treatment steps or algo-
rithms that include both some psychotherapy and anti-
depressant medications [41].
Missing data must also be considered in the prevalence
estimates. For example, if people with severe depression are
less likely to complete the PHQ-9 questionnaire, it could
lead to underestimation of the prevalence of severe depres-
sion symptoms. We examined the missing data pattern,
including individual questions on PHQ-9 questionnaire,
but did not detect any notable patterns in demographic and
general characteristics between people with missing PHQ-9
data and people with complete data. The most common
pattern of missing data is missing all 9 questions.
Conclusions
The prevalence of clinically relevant depression (CRD) and
clinically significant depression (CSD) among people with
T2DM in the US may be lower than in earlier studies, how-
ever, the burden of depression remains high. Psychological
consultation is less than 15 % (Table 3) even for people with
clinically significant depression. All health care providers
should be aware of mental-health comorbidities while treat-
ing a the physical condition of patients with T2DM. Signifi-
cant predictors of both CRD and CSD include younger age,
female sex, lower education level, lower family income, and
trouble sleeping. Specific predictors of CRD also include
smoking, body mass index ≥30 kg/m2, and hospitalization
in the past 12 months; specific predictors of CSD included
physical activity below recommended level, cardiovascular
diseases, and high total cholesterol.
Further research with longitudinal follow-up for de-
pression in people with T2DM is needed to understand
real world effectiveness of depression management.
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